Eisai and Biogen Launch LEQEMBI Pen in Japan for Once-Weekly Alzheimer's Disease Treatment

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®&rdqu...

November 16, 2026 | Monday | News
Minghui Pharmaceutical and ASKA Sign Potential US$440 Million Licensing Deal for Thyroid Eye Disease Drug in Japan

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement for the ...

November 05, 2026 | Thursday | News
AbbVie and Nxera Pharma Sign Potential US$1.47 Billion Licensing Deal for Inflammatory Bowel Disease Drug

Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties...

November 05, 2026 | Thursday | News
HUTCHMED and AstraZeneca Secure Regulatory Review in Europe and Japan for ORPATHYS and TAGRISSO Lung Cancer Combination

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) announces that regulatory filings for ORPATHYS® (savolitinib) in combinati...

November 03, 2026 | Tuesday | News
Ono Pharmaceutical Reports Encouraging Pain Reduction Signals in Phase 2 Trials of ONO-1110

Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...

October 30, 2026 | Friday | News
Astellas Secures Option to License Audax’s DAX-044 Immuno-Oncology Candidate in US$285m Deal

Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax")  announced that they have ent...

October 29, 2026 | Thursday | News
Takeda’s Arcotatug Tavat​​ecan Meets Dual Primary Endpoints in Phase 3 Gastric Cancer Trial

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted...

October 26, 2026 | Monday | News
Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...

October 15, 2026 | Thursday | News
Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Astellas Pharma Inc.announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-t...

September 25, 2026 | Friday | News
Elixir Medical Secures Japan Approval for DynamX Sirolimus-Eluting Coronary Bioadaptor System

Elixir Medical (Milpitas, Calif., and Tokyo) announced that its DynamX® Sirolimus-Eluting Coronary Bioadaptor System for the treatment of cor...

September 16, 2026 | Wednesday | News
Basilea Partner Asahi Kasei Starts Phase 2 Cresemba Study in Children in Japan

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...

September 15, 2026 | Tuesday | News
Ono Pharma Partners With Aitia to Discover New Neurological Disease Targets Using Causal AI

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has entered into a drug ...

September 03, 2026 | Thursday | News
Eisai and Biogen’s LEQEMBI Gains Canada Recommendation for Public Reimbursement in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc., announced that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of...

September 02, 2026 | Wednesday | News
Caliway Advances CBL-514 With U.S. FDA Clearance and Phase 3 Trial Launch

Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced two major clinical mi...

August 27, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close